JP2024501956A5 - - Google Patents

Info

Publication number
JP2024501956A5
JP2024501956A5 JP2023538962A JP2023538962A JP2024501956A5 JP 2024501956 A5 JP2024501956 A5 JP 2024501956A5 JP 2023538962 A JP2023538962 A JP 2023538962A JP 2023538962 A JP2023538962 A JP 2023538962A JP 2024501956 A5 JP2024501956 A5 JP 2024501956A5
Authority
JP
Japan
Prior art keywords
compound
formula
reaction mixture
following
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023538962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501956A (ja
JP7720914B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/139524 external-priority patent/WO2022134033A1/en
Application filed filed Critical
Publication of JP2024501956A publication Critical patent/JP2024501956A/ja
Publication of JP2024501956A5 publication Critical patent/JP2024501956A5/ja
Application granted granted Critical
Publication of JP7720914B2 publication Critical patent/JP7720914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023538962A 2020-12-25 2021-12-22 ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法 Active JP7720914B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/139524 2020-12-25
PCT/CN2020/139524 WO2022134033A1 (en) 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PCT/US2021/064947 WO2022140600A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
JP2024501956A JP2024501956A (ja) 2024-01-17
JP2024501956A5 true JP2024501956A5 (cg-RX-API-DMAC7.html) 2024-07-22
JP7720914B2 JP7720914B2 (ja) 2025-08-08

Family

ID=82157262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538962A Active JP7720914B2 (ja) 2020-12-25 2021-12-22 ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法

Country Status (10)

Country Link
US (2) US12152028B2 (cg-RX-API-DMAC7.html)
EP (1) EP4267577A4 (cg-RX-API-DMAC7.html)
JP (1) JP7720914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230124985A (cg-RX-API-DMAC7.html)
CN (1) CN116867780A (cg-RX-API-DMAC7.html)
AU (2) AU2021410756B2 (cg-RX-API-DMAC7.html)
CA (1) CA3202354A1 (cg-RX-API-DMAC7.html)
IL (1) IL304005A (cg-RX-API-DMAC7.html)
MX (1) MX2023007404A (cg-RX-API-DMAC7.html)
WO (2) WO2022134033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
WO2026132432A1 (en) 2024-12-20 2026-06-25 Curia Spain, S.A.U. Relacorilant crystalline forms

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270488A (en) 1983-09-26 1990-06-19 John M. Schaus Pyrazole-ring alkylated pyrazoloquinolines and intermediates
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DE69430373T2 (de) 1993-08-06 2002-12-12 Smithkline Beecham S.P.A., Baranzate Di Bollate Hydroisochinolinderivate
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JP4498602B2 (ja) 1998-03-10 2010-07-07 リサーチ・トライアングル・インスティチュート 新規なオピエート化合物、その調製法及び使用法
US6166013A (en) 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
AU2620600A (en) 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
CN1547473A (zh) 2001-07-23 2004-11-17 �Ƹ��� 预防由抗精神病药物引起的体重增加的方法
ATE411013T1 (de) 2001-08-31 2008-10-15 Corcept Therapeutics Inc Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1534299A4 (en) 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
AU2004208842B2 (en) 2003-02-04 2009-05-28 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
CA2552419C (en) 2004-01-09 2013-04-23 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
EP1723174A1 (en) 2004-02-26 2006-11-22 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health A novel modulator of glucocorticoid receptor activities
JP4931794B2 (ja) 2004-03-09 2012-05-16 コーセプト セラピューティクス, インコーポレイテッド 縮合環アザデカリン糖質コルチコイド受容体モジュレーター
US7576076B2 (en) 2004-07-02 2009-08-18 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
US20110166115A1 (en) 2008-07-01 2011-07-07 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
BR112013004322A2 (pt) 2010-08-27 2016-06-21 Corcept Therapeutics Inc moduladores de azadecalin fundidos com piridil-aminas
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
ES2991315T3 (es) 2012-02-24 2024-12-03 Univ Chicago Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
NZ701469A (en) * 2012-05-25 2017-06-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
ES2943542T3 (es) 2013-11-25 2023-06-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US10532150B2 (en) 2014-07-21 2020-01-14 Medtronic Minimed, Inc. Smart connection interface
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス, インコーポレイテッド Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
US20180064679A1 (en) 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
AU2017228329B2 (en) * 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
PH12017000049B1 (en) 2017-02-20 2018-08-29 Peter S Heilveil Aerial cable spacer
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
NZ778399A (en) * 2019-02-22 2024-11-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
JP2023515781A (ja) 2020-02-10 2023-04-14 コーセプト セラピューティクス, インコーポレイテッド 選択的グルココルチコイド受容体モジュレーターを使用して抗腫瘍応答を刺激する方法
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2023301396A1 (en) 2022-06-28 2024-12-12 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Similar Documents

Publication Publication Date Title
JP5202635B2 (ja) インテグラーゼ阻害剤の調製のためのプロセスおよび中間体
JP6995178B2 (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
IL197527A (en) 4-oxo-quinolone derivatives and process and intermediates for preparing integrase inhibitors
JP2014524920A5 (cg-RX-API-DMAC7.html)
US9663550B2 (en) Method for preparing abiraterone acetate
CN105636592A (zh) 形成前药的化合物
JP5777513B2 (ja) 高い薬学的純度のソリフェナシン及び/またはその薬学的に受容可能な塩の製造方法
WO2011116490A1 (zh) 制备消旋卡多曲的方法
US9676815B2 (en) Process for the preparation of abiraterone or abiraterone acetate
KR100990046B1 (ko) 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
US20190048017A1 (en) Method for catalytic preparation of hydromorphone, hydrocodone, and other opiates
CN105130982B (zh) 一种咪唑并杂环氨基二硫代甲酸酯及其制备方法
WO2014188445A1 (en) PROCESS FOR THE PREPARATION OF (3β)-17-(3-PYRIDINYL)ANDROSTA-5,16-DIEN-3-YL ACETATE AND POLYMORPH THEREOF
CA3226626A1 (en) Crystal form of compound represented by formula i, and preparation therefor and application thereof
KR101525296B1 (ko) 라미부딘 옥살레이트 및 이의 제조방법
CN108727214B (zh) 一种麻醉剂丁哌卡因杂质的合成方法
CN106279117A (zh) 一种雷迪帕韦中间体的合成方法及其产品
CN101104601B (zh) 一种新的扎鲁司特重要中间体的制备方法
CN109956938A (zh) 乌美溴铵中间体晶型及其制备方法和以该中间体制备乌美溴铵的方法
WO2020023438A2 (en) Process for the preparation of bromodomain inhibitor
US20240368211A1 (en) Processes of making onapristone and intermediates thereof
CN101151256B (zh) 二苯并*庚因衍生物的制造方法
CN111100063B (zh) 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法
CN114286811B (zh) 富马酸单甲酯的前药
US20120267533A1 (en) Processes for the preparation of form i and form ii of palonosetron hydrochloride